Cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment
Credit: Pixabay/CC0 Public Domain An important discovery from the NCI-MATCH precision medicine initiative is published in Clinical Cancer Research, Trastuzumab-pertuzumab, a drug combination approved by the US Food and Drug Administration (FDA) to treat patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, shrank tumors in patients with several other types of cancer …